VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 127 filers reported holding VAXCYTE INC in Q3 2022. The put-call ratio across all filers is 0.98 and the average weighting 0.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $359,911,596 | +2.1% | 7,060,588 | +0.0% | 0.24% | +7.8% |
Q2 2023 | $352,559,989 | +32.0% | 7,059,751 | -1.0% | 0.22% | +24.4% |
Q1 2023 | $267,146,529 | -6.7% | 7,127,611 | +19.3% | 0.18% | -14.1% |
Q4 2022 | $286,454,808 | +162.8% | 5,974,139 | -34.2% | 0.20% | +150.0% |
Q3 2022 | $109,016,908 | +18.6% | 9,075,502 | +114.8% | 0.08% | +30.2% |
Q2 2022 | $91,935,000 | -12.1% | 4,224,487 | -2.4% | 0.06% | +26.0% |
Q1 2022 | $104,556,000 | +3.5% | 4,329,764 | +2.0% | 0.05% | +19.0% |
Q4 2021 | $101,035,000 | -2.7% | 4,246,664 | +3.7% | 0.04% | -6.7% |
Q3 2021 | $103,851,000 | +12.1% | 4,093,466 | -0.6% | 0.04% | +12.5% |
Q2 2021 | $92,673,000 | +10.9% | 4,116,959 | -2.7% | 0.04% | +5.3% |
Q1 2021 | $83,547,000 | -22.3% | 4,230,307 | +0.8% | 0.04% | -24.0% |
Q4 2020 | $107,538,000 | -46.2% | 4,196,778 | +0.0% | 0.05% | -51.9% |
Q3 2020 | $199,839,000 | +42.8% | 4,196,429 | -11.2% | 0.10% | +31.6% |
Q2 2020 | $139,934,000 | – | 4,725,792 | – | 0.08% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Abingworth LLP | 4,168,718 | $90,711,000 | 29.04% |
Medicxi Ventures Management (Jersey) Ltd | 3,774,956 | $82,142,000 | 17.06% |
Pivotal bioVenture Partners Investment Advisor LLC | 832,166 | $18,108,000 | 9.12% |
GREAT POINT PARTNERS LLC | 985,153 | $21,437,000 | 5.14% |
Kynam Capital Management, LP | 723,781 | $15,749,000 | 4.02% |
Ghost Tree Capital, LLC | 325,000 | $7,072,000 | 3.68% |
Frazier Life Sciences Management, L.P. | 1,787,405 | $38,894,000 | 3.67% |
RA Capital Management | 4,581,203 | $99,687,000 | 2.66% |
Opaleye Management Inc. | 190,000 | $4,134,000 | 1.86% |
Soleus Capital Management, L.P. | 370,650 | $8,065,000 | 1.26% |